Orna Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $221M
Overview
A biotechnology company pioneering circular RNA therapeutics for more durable and potent protein expression.
OncologyInfectious Disease
Technology Platform
A proprietary platform for designing and delivering engineered circular RNA (oRNA) molecules, which offer enhanced stability and prolonged protein expression compared to linear mRNA.
Funding History
1Total raised:$221M
Series C$221M
Opportunities
Circular RNA could enable single-dose vaccines and durable in vivo cell therapies, expanding RNA's therapeutic reach.
Risk Factors
Unproven clinical safety and efficacy, alongside complex manufacturing scale-up for a novel modality.
Competitive Landscape
A frontrunner in circular RNA, competing against linear mRNA giants and other novel RNA modality companies.